ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination with Rituximab and Bendamustine vs Placebo Administered in Combination with Rituximab and Bendamustine in Subjects with Previously-Treated Indolent Non-Hodgkin Lymphoma
EudraCT number 2015-004033-28
Protocol number IPI-145-22
Sponsor Infinity Pharmaceuticals, Inc.,784 Memorial Drive,Cambridge, MA,02139, United States
Indications Hemato-oncology
Diagnosis Indolent Non-Hodgkin Lymphoma
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2016
Date of approval by Institute (SÚKL) 13.4.2016
Date of approval by EC
Date of initiation CT in ČR
Date of ending CT in ČR 13.7.2016
Sites Fakultní nemocnice Královské Vinohrady,Interní hematologická klinika,Šrobárova 50,Praha 10,10034
Fakultní nemocnice Hradec Králové,IV. interní hematologická klinika,Sokolská 581,Hradec Králové,50005
Fakultní nemocnice Ostrava,klinika hematoonkologie,17. listopadu 1790,Ostrava-Poruba,70852

‹‹ Back to list